âWe have generated a lot of interest from the general public wanting to buy our COVID-19 tests: from parents who need to keep their children healthy in school to international business travelers to families who want to get together safely during the holiday season. are excited to make Cue available to a wider audience next week to provide fast and accurate COVID-19 testing at home or on the go, âsaid Clint sever, co-founder and product manager of Cue.
Cue + membership not only meets people’s home testing needs, but also allows them to share Cue test results and discuss other health concerns with a doctor on demand in the new Cue app. Health. The Cue platform is integrated with last mile delivery services so members can get products home when they need it most. And as expected COVID-19 antivirals requiring rapid administration hit the market, Cue expects to be able to allow consumers to go from test result to seeing a doctor and taking antiviral treatment, as the case may be. appropriate, in the comfort and convenience of their own homes.
“We are excited to be able to offer consumers our best COVID-19 tests as part of Cue’s Integrated Care Platform, which we believe can help individuals and families live their healthiest lives,” said Ayub Khattak, co-founder and CEO of Cue. “With membership in Cue + and our new Cue Health app, we aim to make the healthcare journey – from testing to diagnosis to treatment – more accessible, more convenient and faster.”
The Cue experience begins with the Marker reader ($ 249), a reusable, compact device that processes each test and connects wirelessly with a user’s mobile device to deliver results in 20 minutes via the Health Cue App (for iOS and Android). The Cue player is compatible with Cue COVID-19 Test Cartridge ($ 225/ 3 pack) and other tests under development. Cue’s COVID-19 Tests are single-use, stand-alone cartridges that make testing simple and convenient. These products will be bundled together for discounts and available for purchase under two new Cue + membership packages when shop.cuehealth.com starts on November 15.
Features of the Cue + subscription:
- Cue + Essential â¢ ($ 49.99/month): Convenient, easy-to-use, lab-grade home testing and Cue Virtual Care to meet your needs anytime, anywhere. Ten COVID-19 tests per year, 20% off additional COVID-19 tests, and free same-day delivery in select markets. Reduced price on the Cue Reader (sold separately).
- Cue + Complete â¢ ($ 89.99/month): all the benefits of Cue + Essential, plus supervised, CDC-compliant COVID-19 testing for travel, work, or school. Even more COVID-19 tests (20 per year) and frontline access to future Cue care offerings.
Cue’s virtual healing capabilities will include:
- CDC-compliant test results via in-app video surveillance for travel, work, and school (for Cue + Complete members)
- 24/7 access to chat with certified doctors
- New electronic prescriptions and prescription renewals
- Laboratory tests ordered by a doctor
Cue aims to provide individuals with the ability to proactively monitor and manage their health, with actionable information they can share with healthcare providers in real time. Future care offerings planned by Cue – all of which are designed to be compatible with the Cue Reader – include products and services in the categories of respiratory health (such as influenza, RSV and strep throat), sexual health (as with chlamydia and gonorrhea), heart and metabolic health (as with cholesterol and HbA1c), women’s and men’s health, and chronic disease management.
For more information on Cue products and services available at November 15, please visit cuehealth.com.
Please download press material to accompany today’s announcement here.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company that puts consumers in control of their health information and puts diagnostic information at the center of care. Cue Health empowers people to manage their health with real-time, actionable, and connected health information, giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, no whenever, in a device that fits in the palm of your hand. The COVID-19 test, the first of its kind from Cue Health, was the first molecular diagnostic test cleared by the FDA for home and over-the-counter use without a prescription or physician supervision. Outside United States, Cue Health has received the CE Mark in the European Union, Interim Prescription Authorization from Health Canada and regulatory approval from india Central pharmaceutical standards control organization. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
Statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, without limitation, “anticipate”, “believe”, “continue”, “could”, “estimate”, “‘wait”, “project”, “should”, “target”, “will”, âWouldâ and similar phrases are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated in these forward-looking statements due to various important factors, including the factors discussed in the âRisk Factorsâ section of the prospectus dated September 23, 2021 filed by Cue with the SEC. All forward-looking statements contained in this press release are based on the current expectations of Cue’s management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
The COVID-19 Cue Test for Home and Over-the-Counter (OTC) Use and the COVID-19 Cue Test (for Professional Use) have not been authorized or approved by the FDA; but have been cleared by the FDA under an Emergency Use Clearance (EUA). These products have been authorized only for the detection of SARS-CoV-2 nucleic acid, not for other viruses or pathogens. Emergency use of these products is only authorized for the duration of the declaration of the existence of circumstances justifying the authorization of emergency use of in vitro diagnostics for the detection and / or diagnosis of COVID -19 under Section 564 (b) (1) of the Federal Law. Food, Drug and Cosmetic Act, 21 USC Â§ 360bbb-3 (b) (1), unless the statement is terminated or the authorization is earlier revoked.
1 In an independent study conducted by Mayo Clinic Laboratories, the overall agreement between Cue’s point-of-care test and reference laboratory tests was found to be 97.8%. Details of the study can be found here.
SOURCE Cue SantÃ© Inc.